SPIA
MCRB icon

Steward Partners Investment Advisory’s Seres Therapeutics MCRB Stock Holding History

Steward Partners Investment Advisory’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-20
Closed -$10K – 3257
2021
Q2 		$10K Sell
20
-50
-71% -$21.1K ﹤0.01% 6059
2021
Q1 		$28.8K Buy
70
+50
+250% +$23K ﹤0.01% 2284
2020
Q4 		$10K Hold
20
– – ﹤0.01% 2315
2020
Q3 		$11K Buy
+20
New +$6.65K ﹤0.01% 2104
2018
Q3 		– Sell
-20
Closed -$3K – 2646
2018
Q2 		$3K Buy
+20
New +$3.27K ﹤0.01% 2130

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Steward Partners Investment Advisory's MCRB Position: Q3 2021 in Review

Steward Partners Investment Advisory sold out of Seres Therapeutics (MCRB) in Q3 2021, closing a stake of 20 shares — an estimated $10K sold.

Steward Partners Investment Advisory first reported a position in MCRB in Q2 2018 and held it in 5 quarters. The position peaked at $28.8K in Q1 2021. 133 funds tracked by Wall St. Rank hold MCRB as of Q3 2021.

  • Steward Partners Investment Advisory reported no remaining Seres Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 20 Seres Therapeutics shares in Q3 2021, an estimated $10K.
  • Steward Partners Investment Advisory first reported a position in Seres Therapeutics in Q2 2018 and held it in 5 quarters.
  • Steward Partners Investment Advisory's Seres Therapeutics position peaked at $28.8K in Q1 2021.
  • 133 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2021.

Based on Steward Partners Investment Advisory's 13F filing for Q3 2021, filed 12 Nov 2021.